Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
38262
CAS Number:
674773-07-0
Hidrato de ranelato de estroncio
Purity:
≥ 98 % (HPLC)
Synonym(s):
Ácido ranélico Hidrato de sal de estroncio
Documents
$115.27 /1G
Tamaño
Request Bulk Quote
Información del producto

Strontium ranelate hydrate is a unique compound recognized for its potential in the treatment of osteoporosis and bone health enhancement. This innovative therapeutic agent functions by promoting bone formation while simultaneously inhibiting bone resorption, making it a valuable option for patients at risk of fractures. Its dual action is particularly beneficial in managing conditions associated with low bone density, providing a comprehensive approach to bone health. Researchers and healthcare professionals appreciate its ability to improve bone mineral density and reduce the incidence of vertebral and non-vertebral fractures, which is crucial for patient care in geriatric populations.

In addition to its medical applications, strontium ranelate hydrate is also being explored in various research settings for its potential in biomaterials and regenerative medicine. Its unique chemical structure allows for versatile applications, including the development of new therapeutic strategies for bone-related disorders. The compound's stability and efficacy make it an attractive candidate for further studies, paving the way for advancements in both clinical and research environments.

Número CAS
674773-07-0
Fórmula molecular
C12H6N2O8SSr2 · xH2O
Peso molecular
513.49
Número MDL
MFCD09038742
Condiciones
Conservar a < 0 °C
Información general
Número CAS
674773-07-0
Fórmula molecular
C12H6N2O8SSr2 · xH2O
Peso molecular
513.49
Número MDL
MFCD09038742
Condiciones
Conservar a < 0 °C
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Strontium ranelate hydrate is widely utilized in research focused on:

  • Osteoporosis Treatment: This compound is primarily used in the pharmaceutical industry for the treatment of osteoporosis, helping to increase bone density and reduce fracture risk in postmenopausal women.
  • Bone Health Research: Researchers use strontium ranelate hydrate to study its effects on bone metabolism, providing insights into how it can enhance bone formation and inhibit bone resorption.
  • Drug Formulation Development: In the development of new medications, this compound serves as a model for creating effective formulations aimed at improving bioavailability and therapeutic efficacy.
  • Clinical Trials: It is frequently used in clinical trials to evaluate its long-term safety and effectiveness, contributing to the advancement of treatment protocols for osteoporosis.
  • Comparative Studies: Strontium ranelate hydrate is often compared with other osteoporosis treatments, allowing researchers to assess its unique advantages, such as a dual mode of action that supports both bone formation and decreases bone resorption.

Citas